menu
    • menu

    Company profile for Eiger BioPharmaceuticals

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Eiger is a late stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases. We innovate by developing well-characterized drugs in newly identified or novel targets in rare diseases. Our mission is to systematically reduce the time and cost of the drug development process to more rapidly deliver important medicines to patients. The company’...
    Eiger is a late stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases. We innovate by developing well-characterized drugs in newly identified or novel targets in rare diseases. Our mission is to systematically reduce the time and cost of the drug development process to more rapidly deliver important medicines to patients. The company’s lead program is in Phase 3, developing lonafarnib, a first-in-class prenylation inhibitor for the treatment of Hepatitis Delta Virus (HDV) infection.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Eiger BioPharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2155 Park Boulevard Palo Alto, CA 94306
    Telephone
    Telephone
    1-650-272-6138
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.eigerbio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Amylyx Rebuilds Momentum Following Relyvrio Market Withdrawal
    Amylyx Rebuilds Momentum Following Relyvrio Market Withdrawal

    24 Jul 2024

    // BIOSPACE

    https://www.biospace.com/drug-development/amylyx-rebuilds-momentum-following-relyvrio-market-withdrawal

    BIOSPACE
    24 Jul 2024
    Share Share
    Amylyx Acquires Phase 3 GLP-1 Antagonist With FDA Breakthrough Status
    Amylyx Acquires Phase 3 GLP-1 Antagonist With FDA Breakthrough Status

    10 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240710172870/en

    BUSINESSWIRE
    10 Jul 2024
    Share Share
    Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
    Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar

    22 Jun 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/amylyx-buy-bankrupt-eigers-experimental-drug-treat-low-blood-sugar-2024-06-21/

    REUTERS
    22 Jun 2024
    Share Share
    Sentynl Acquires Zokinvy® For Progeria From Eiger Globally
    Sentynl Acquires Zokinvy® For Progeria From Eiger Globally

    03 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sentynl-therapeutics-announces-global-acquisition-of-zokinvy-lonafarnib-for-treatment-of-hutchinson-gilford-progeria-syndrome-from-eiger-biopharmaceuticals-302135968.html

    PR NEWSWIRE
    03 May 2024
    Share Share
    Eiger Files for Bankruptcy, Plans to Shutter Operations After Difficult Year
    Eiger Files for Bankruptcy, Plans to Shutter Operations After Difficult Year

    02 Apr 2024

    // BIOSPACE

    https://www.biospace.com/article/eiger-files-for-bankruptcy-plans-to-shutter-operations-after-difficult-year/

    BIOSPACE
    02 Apr 2024
    Share Share
    Eiger files for bankruptcy and will wind down operations after years of setbacks
    Eiger files for bankruptcy and will wind down operations after years of setbacks

    01 Apr 2024

    // Kyle LaHucik ENDPTS

    https://endpts.com/eiger-files-for-bankruptcy-and-will-wind-down-operations-after-years-of-setbacks/

    Kyle LaHucik ENDPTS
    01 Apr 2024
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search